|
Daily Medical Update
Obesity
Monday, August 24, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The Cochrane database of systematic reviews (2026) - Network Meta-Analysis
Key Findings
- At long-term follow-up, Roux-en-Y gastric bypass produced 16.95 percentage points more weight loss than lifestyle or medical treatment (95% CI, 9.71 to 24.19).
- Roux-en-Y gastric bypass reduced waist circumference by 12.34 cm versus lifestyle or medical treatment (95% CI, 6.81 to 17.88) and lowered HbA1c by 1.44 percentage points (95% CI, 0.63 to 2.26).
📋 Practice Implication: For adults with obesity and type 2 diabetes, discuss metabolic surgery—particularly Roux-en-Y gastric bypass—as a durable option when nonsurgical treatment is inadequate, while counseling that certainty remains limited for remission and harms.
|
BMJ (Clinical research ed.) (2026) - Network Meta-Analysis
Key Findings
- At one year versus lifestyle modification alone, tirzepatide reduced weight by 14.9% (95% CI, 13.9% to 16.0%) and oral semaglutide by 10.9% (95% CI, 9.1% to 12.7%).
- Gastrointestinal events increased with several agents (risk ratios 3.1 to 4.2), while subcutaneous semaglutide was associated with lower all-cause mortality (RR 0.81) and myocardial infarction (RR 0.72).
📋 Practice Implication: Use the comparative efficacy data for shared decisions: larger expected weight reduction generally comes with more treatment-limiting adverse effects, while cardiovascular outcome evidence is concentrated in subcutaneous semaglutide.
|
Annals of internal medicine (2026) - Practice Guideline
Key Findings
- ACP recommends semaglutide and tirzepatide as first-line pharmacologic options with lifestyle modification for adults with obesity (BMI ≥30 kg/m²), based on moderate-certainty evidence for weight reduction.
- For adults with overweight plus a comorbidity, semaglutide and tirzepatide remain first-line options for weight reduction; liraglutide is the second-line option.
📋 Practice Implication: Apply the ACP sequence as an outpatient starting framework, then individualize medication choice around contraindications, pregnancy considerations, access, cost, comorbidities, and patient weight-loss goals.
|
Endocrinology, diabetes & metabolism (2026) - Meta-Analysis
Key Findings
- Tirzepatide 15 mg or the maximum tolerated dose reduced body weight 18.04% more than placebo (95% CI, 16.22% to 19.86%; p<0.00001).
- Relative weight loss was similar in Asian and non-Asian trials (18.16% vs 17.92%; p=0.94), while absolute weight loss was greater in non-Asian participants (23.46 vs 16.72 kg; p=0.03).
📋 Practice Implication: When counseling across ethnic groups, emphasize the broadly similar relative response and avoid interpreting the larger absolute loss in non-Asian participants as a proven biological difference; subgroup safety interactions were not significant.
|
Medicine (2026) - Meta-Analysis
Key Findings
- Subcutaneous semaglutide produced 11.85% greater weight loss than placebo in nondiabetic adults (95% CI, 10.90% to 12.81%; p<0.00001).
- Gastrointestinal adverse events were more frequent, and discontinuation because of adverse events was higher (RR 2.62; 95% CI, 1.70 to 4.03; p=0.001), while serious adverse events were uncommon.
📋 Practice Implication: For nondiabetic adults considering semaglutide, pair the expected weight benefit with anticipatory gastrointestinal counseling, titration support, and early review of tolerability to reduce avoidable discontinuation.
|
|
💡
Summary
The latest evidence supports metabolic surgery for durable weight and glycemic improvements in adults with obesity and type 2 diabetes, although certainty is limited for some longer-term outcomes. Tirzepatide and semaglutide produce substantial weight loss, with gastrointestinal adverse effects and treatment discontinuation requiring attention. The ACP guideline places semaglutide and tirzepatide first-line with lifestyle modification in eligible outpatient adults.
|
|